China has launched a high-profile campaign against purported corruption among foreign pharmaceutical companies this summer.
Chinese authorities have recently brought intense pressure to bear on foreign drug makers over alleged bribery.
Ongoing SEC and Justice investigations and a compliance program included in a shareholder settlement added to the expenses.
At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca.
If GSK isn’t the only pharmaceutical company under investigation by Chinese authorities, a look to the list of drug makers whose conduct in China has also been probed by the United States may offer clues to the others.
After settling with the U.S. for $60 million, the company now faces a shareholder suit in New York saying its poor FCPA compliance damaged shareholder equity.
As companies put a greater emphasis on compliance, the imposition of an outside monitor has become less common.
Kerry Harvey, the U.S. Attorney for the Eastern District of Kentucky, announced the appointment of a new First Assistant and chief of the office’s civil division.
Though companies now are required to admit to facts alleged by the Justice Department to settle parallel civil investigations, other similar conduct goes unacknowledged.
The DOJ’s FCPA unit chief discusses rogue employees, FCPA guidance, why even anonymized declinations will continue to be rarely disclosed, and the busy year facing prosecutors.
The Justice Department’s Foreign Corrupt Practices Act unit chief spoke via telephone at the American Bar Association’s white collar crime conference in Las Vegas.
The CEO, chairman of the board and chief compliance officer have all be removed as a result of a foreign bribery investigation involving shares in a former Taiwan subsidiary.
Three health care industry companies were among the biggest apparent beneficiaries of tax laws allowing deduction of disgorgement and pre-judgment interest, a Just Anti-Corruption analysis found.
The Justice Department and SEC secured roughly $260 million from FCPA settlements for the year.
The company will pay almost $30 million to resolve allegations of bribery in China, Russia, Brazil and Poland.
The government almost always links alleged foreign bribery conduct to the United States — but with U.S. companies, it doesn’t have to.
Pharmaceutical giant Pfizer Inc., which settled a self-disclosed Foreign Corrupt Practices Act matter in August, has an open door policy regarding whistleblowers, in-house counsel Sarah Chopp told an American Bar Association conference in Washington, D.C.
The SEC routinely scrubs its rolls of void and dissolved companies – actions that help the agency build its enforcement statistics.
Advocates of Foreign Corrupt Practices Act reform returned to Capitol Hill on Friday to press their case, signalling that business interests haven’t given up on persuading Congress eventually to amend the statute despite recent adverse publicity over such foreign bribery cases as Wal-Mart Stores Inc.
Agreement on the fine and disgorgement had reportedly been reached in November.
Marc Smolonsky, associate deputy secretary at the Department of Health and Human Services, was among the panelists on Capitol Hill for the Main Justice forum: “What’s Next? Strategies for Improving Compliance with Fraud and Abuse Laws.”
The industry-wide corruption probe, announced in a 2009 speech by DOJ Criminal Division chief Lanny Breuer, stemmed from internal investigations by Pfizer and rival Johnson & Johnson.
The Justice Department and the Securities and Exchange Commission have been examining since 2004 whether the company violated the Foreign Corrupt Practices Act.
Michael Horowitz disclosed a multimillion dollar salary, multinational clients, and millions invested in mutual funds.
A group of socially-conscious investors asked the companies to review their roles at the lobbying powerhouse. Just Anti-Corruption broke the story last month of the Chamber’s FCPA lobbying.
Nancy Boswell is departing after “considerable reflection” and 17 often troubled years.
House Judiciary Committee Chairman Lamar Smith (R-Texas) said the House will offer its own patent reform bill.
The investigation dates back to 2004, when the company began providing details to agencies about potential bribes in connection with sales overseas.
The Senate Judiciary Committee earlier this month backed the legislation without opposition.
The Senate Judiciary Committee last week approved its patent reform bill without opposition.
"He certainly comes at the law from a prosecutor's perspective." -- William Yeomans on DOJ official Roy Austin, the leading candidate to head ICE.